The FDA has approved Pfizer’s bevacizumab biosimilar, bevacizumab-bvzr, referencing Avastin.
The FDA has approved Pfizer’s bevacizumab biosimilar, bevacizumab-bvzr, referencing Avastin. The biosimilar will be sold as Zirabev. The drug has been approved for the treatment of metastatic colorectal cancer, recurrent or metastatic nonsquamous non—small cell lung cancer (NSCLC), recurrent glioblastoma, metastatic renal cell carcinoma, and persistent, recurrent, or metastatic cervical cancer.
“Biosimilars like Zirabev can help increase access to impactful therapies, driving market competition that may ultimately lower costs and help address the diverse needs of patients living with cancer,” Andy Schmeltz, global president of Pfizer Oncology, said in a statement. “We are proud to add Zirabev to our growing oncology portfolio for US patients living with a wide variety of tumor types.”
Among the data Pfizer generated in support of the biosimilar’s approval were those from the REFLECTIONS B7391003 study, a comparative, confirmatory safety and efficacy study of the biosimilar versus the reference bevacizumab. The trial enrolled 719 patients with advanced nonsquamous NSCLC. The study demonstrated equivalence in the primary end point of objective response rate of the biosimilar versus the reference when taken in combination with carboplatin/paclitaxel for first-line treatment of NSCLC.
Additionally, a phase 1 pharmacokinetic (PD) study1 of the biosimilar was conducted in 102 healthy males volunteers. In the double-blind study, the volunteers received single 5 mg per kg intravenous doses of either the biosimilar, the EU-licensed reference product, or the US-licensed reference product. PK similarity was achieved if 90% CIs for the test-to-reference ratios of the maximum serum concentration, area under the serum concentration—time curve from zero to infinity, and from zero to time of last quantifiable concentration fell within the 80% to 125% bioequivalence acceptance window. The 90% CIs for all 3 parameters fell within the prespecified margin.
Pfizer’s biosimilar is also approved in the European Union; Zirabev earned the European Commission’s approval in February 2019 after having received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use in December 2018.
Pfizer’s biosimilar joins Amgen’s Mvasi in the ranks of FDA-approved bevacizumab biosimilars, although it remains to be seen which product will be first to the US market; while Mvasi was approved in the United States in 2017, it has not yet been launched.
Reference
1. Knight B, Rassam D, Liao S, Ewesuedo R. A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers. Cancer Chemother Pharmacol. 2016;77(4):839-46. doi: 10.1007/s00280-016-3001-2.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.